Sub-dissociative dose ketamine administration for managing pain in the emergency department

Sergey Motov, Jefferson Drapkin, Antonios Likourezos, Joshua Doros, Ralph Monfort, John Marshall

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA

Corresponding Author: Jefferson Drapkin, Email: jdrapkin@maimonidesmed.org

BACKGROUND: We describe our experience of utilizing sub-dissociative dose ketamine (SDK) in managing a variety of acute and chronic painful conditions in the emergency department (ED).

METHODS: A descriptive study was conducted in our ED over a period of seven years (2010–2016) by retrospectively reviewing charts of patients aged 18 and older presenting to the ED with painful complaints and receiving SDK analgesia. Primary data analyses included type of SDK administration (intravenous push [IVP], short-infusion [SI] or continuous infusion [CI]), dosing, rates of analgesic utilization before and after SDK administration, and adverse effects.

RESULTS: Three hundred sixty-two patients were enrolled in the study. Mean ketamine doses given by IVP, SI and CI were 26.3 mg, 23.4 mg, and 11.3 mg. The mean duration of CI was 135.87 minutes. The percentage of patients not requiring post-SDK analgesia increased by 16%, 18%, and 37% in IVP, SI and CI groups. Adverse effects were recorded for 13% of patients.

CONCLUSION: SDK administered by IVP, SI, and CI in the ED for a variety of painful conditions is a feasible analgesic modality in the ED that is associated with a decrease in overall requirements of post-ketamine analgesia and opioid sparing.

KEY WORDS: Ketamine; Analgesia; Emergency department; Sub-dissociative; Infusion
experience with SDK analgesia in the ED with respect to type of SDK administration (IVP, SI or CI), dosing range, co-analgesic administration, and rates of side effects. We hypothesized that this analgesic modality can be utilized in the ED across wide range of acute and chronic painful conditions and that its administration may lead to reduced co-analgesic (opioids, non-opioids) administration and minimal risk for serious adverse effects.

METHODS
Study design and setting
We retrospectively reviewed medical charts of patients who were admitted to our ED and received SDK analgesia over a six-year period (2010–2016). The study was conducted at a 711-bed urban community teaching hospital with an annual ED census of greater than 120,000 visits. In our ED, the predominant route of SDK administered is a short infusion with a weight-based dose of 0.3 mg/kg given over 15 minutes. Additionally, we use continuous SDK infusion with a starting dose of 0.15 mg/(kg•h) that is titrated up as necessary by the treating physician every 20–30 minutes by 2.5–5 mg and intravenous weight-based push dose of SDK of 0.3 mg/kg given over 3–5 minutes. Weight-based intravenous SDK order sets are built into our electronic medical record system (Allscripts™), prepared by ED pharmacists, and administered by ED nursing staff via infusion pump. All patients requiring continuous SDK infusion are placed on a cardiac monitor with continuous pulse oximetry. This study was approved by the hospital’s institutional review board.

Selection of participants
Patients 18 years and older presenting with a variety of acute and chronic painful conditions for which they received SDK analgesia in the ED were eligible for the study. Patients were excluded if they had received intravenous ketamine for a purpose other than analgesia, such as for procedural sedation, anxiolysis, or end-of-life care; or if patients were enrolled in SDK-related research projects.

Methods and measurements
Data collection was performed by querying the ED electronic medical record (Allscripts™) database. Data extracted included: age, sex, chief complaint, final diagnoses, pre- and post-SDK dosing, time range for continuous infusion, analgesics administered before and after SDK administration, and adverse effects.

Outcomes
The primary outcomes were: (1) dosing for intravenous push, short infusion and continuous infusion and duration of the continuous ketamine infusion within each group and with respect to final diagnoses; (2) percentage of patients receiving analgesic medications before and after SDK administration; and (3) overall rates of adverse effects for intravenous push dose, short- and continuous infusions.

Data analysis
The data analyses consisted primarily of descriptive statistics: baseline characteristics of patients in each treatment group were described in terms of mean±standard deviation for continuous variables and frequency (percent) for categorical variables. Student’s t-test was used to compare simple group differences in terms of means (e.g., age), while the chi-square test was used to look at differences in terms of percent rates (e.g., sex). All statistical analyses were carried out using SPSS v.24 (IBM Corp., Armonk, NY, USA).

RESULTS
We reviewed 2,781 medical records containing orders for ketamine which occurred between January 2010 and December 2016 (Figure 1). Of those, 2,419 patient records were excluded due to ketamine use other than for analgesia. The remaining 362 subjects who received SDK for pain control were enrolled in the study, with 49 patients in the intravenous push (IVP)
group, 209 in the short infusion (SI) group, and 104 in the continuous infusion (CI) group. The mean age was 48.8 years old, with 39.2% male patients. The majority of patients who received SDK analgesia presented with chief complaints related to abdominal pain (31.2%) and musculoskeletal pain (22.1%) which roughly correlated with final diagnoses.

**Main outcomes**

The mean SDK dose for IVP was 26.3 mg (10–50 mg), for SI was 23.4 mg (6–50 mg), and for CI was 11.3 mg/hour (6.0–22.50 mg/hour) with a mean CI duration of 135.87 minutes (20–480 minutes). Patients in the 30–49 years age group received the highest mean dose (29.3 mg) of SDK given via IVP, 50–69 years age group received the highest mean dose (24 mg) for SI, and 30–49 years age group (12.2 mg/hour) for CI. The 30–49 years age group also received the longest mean CI duration of 140.6 minutes (Figure 2). Upon comparing the dosing range of SDK across final diagnoses, patients with chronic pain and non-traumatic chest pain received the largest mean doses (40 mg and 36 mg) via IVP route, patients with musculoskeletal pain and vaso-occlusive painful crisis received the largest mean doses (26.6 mg and 26.7 mg) via SI route, and patients with chronic pain and renal colic pain received the largest mean doses (13.4 mg and 13.5 mg) via CI route (Figure 3).

Figure 4 shows the percentages of patients who received...
analgesia before and/or after SDK administration. We observed a decrease in post-SDK opioid administration in the IVP group from 33% to 26% ($P=0.825$) and from 36% to 27% ($P=0.046$) in the SI group. In addition, we noticed a significant increase in the percentage of patients not requiring post-SDK analgesia administration in all three groups: from 28% to 45% ($P=0.145$) in the IVP group, from 27% to 44% ($P<0.0001$) in the SI group, and from 12% to 49% ($P<0.0001$) in the CI group. The CI group showed a slight overall increase in opioid requirements after SDK administration (from 18% to 23%, $P=0.490$). Twenty-four patients (6.6%) received SDK without any other analgesics, and 62 patients (59.6%) out of 104 received the SDK bolus dose of 0.3 mg/kg prior to the continuous infusion.

Administration of analgesics before and after SDK varied greatly amongst the five most prevalent clinical diagnoses groups. Patients with abdominal, musculoskeletal, and neuropathic pain were found to have significant differences in not receiving any analgesic pre-and post-SDK administration: 17.7% to

![Figure 4](image4.png)  
**Figure 4.** The percentages of patients who received analgesia before and/or after SDK administration.

![Figure 5](image5.png)  
**Figure 5.** Total analgesics administered pre- & post-ketamine for most common final diagnoses.
52.2% ($P<0.0001$), 21.3% to 46.3% ($P<0.001$), and 17.5% to 42.1% ($P<0.004$), respectively. Furthermore, patients with abdominal pain had significant decrease in post-SDK opioid analgesic administration from 37.2% to 20.4% ($P<0.005$) (Figure 5).

Three hundred and sixteen (87.3%) patients had no documentation of adverse effects. For remaining 46 patients (12.7%), 8 adverse effects were reported (Figure 6).

Three hundred forty-four patients (95%) had documented pre-SDK administration NRS pain scores and 215 (59%) post-administration. However, we were unable to make any assertion with respect to analgesic efficacy of SDK due to the facts that retrospective pain scores are unreliable and insufficiently precise in evaluating pain relief solely attributed to ketamine.

**DISCUSSION**

SDK administration in the form of intravenous push or short infusion is becoming increasingly popular as a viable adjunct to or substitute for opioid analgesics for managing a variety of acute and chronic painful conditions in the pre-hospital arena and in the ED. Retrospective case series, prospective observational, and randomized controlled trials have demonstrated good (even comparable to morphine) analgesic efficacy and modest rates of minor but bothersome side effects of SDK given as an intravenous push dose for ED patients with acute pain.[4–13]

The most recent data support the use of a short infusion of SDK (over 15 minutes) as a preferred route due to the fact that it resulted in a significant decrease of such side effects (by 40%) with preserved analgesic efficacy.[14,15] Of note, there is a paucity of data supporting the use of continuous SDK infusion (longer than 1 hour) in the ED despite a growing body of literature that advocates for utilization of continuous intravenous ketamine infusion either as an adjunct to opioids or as a single agent for pediatric and adult patients with predominantly chronic painful conditions.[16–19]

Our retrospective chart review demonstrates feasibility of SDK administration in the ED for a variety of acute and chronic painful conditions via intravenous push, short and continuous infusions across different age groups and across a variety of painful syndromes with a potential for opioid sparing and a reduced need for rescue analgesics administration.

Despite the low overall number of patients (13%) with documented adverse effects, we cannot truly make any recommendations regarding the safety of SDK in the ED, however, we did not find any documented reports of major adverse effects that required interventions. Despite the trend towards higher rates of adverse effects in the short-infusion group, we believe that this route of SDK administration confers the best option in the ED based on the number of patients enrolled and overall change in pain scores.

The fact that SDK administration via IVP, SI and, especially, CI routes resulted in significant reduction of post-ketamine analgesic use by 16%, 18% and 37% respectively is very encouraging. Furthermore, the decrease in opioid requirements in the IVP and SI groups by 6% and 8.5% post-SDK administration demonstrates the opioid-sparing properties of SDK. In addition, our study showed significant decreases in overall post-SDK analgesics administration for patients with abdominal, musculoskeletal, and neuropathic pain by 35%, 25%, and 25%, respectively, which could have reduced the length of stay and improved overall throughput of such patients in the ED.

Our data showed that SDK analgesia can be employed for geriatric patients with a broad range of painful syndromes in the ED, thus adding an additional analgesic modality with a potential for use when opioids and non-steroidal anti-inflammatory drugs are contraindicated. Furthermore, our recently published study that specifically evaluated a role of continuous SDK infusions in the ED demonstrated an average decrease in pain score of 5.04; average dosing of infusion of 11.26 mg/hr with average duration time of 136 min, and nausea being the most prevalent adverse effect.[20] Thus we believe that continuous SDK infusion has a role in controlling pain in the ED with a potential to reduce the need for co-analgesics or rescue analgesics administration.

![Figure 6. Reported adverse effects.](www.wjem.com.cn)
Despite the ever-growing body of evidence (including prospective randomized blinded studies) that support the use of SDK for managing pain in the ED and in pre-hospital setting, several barriers exist that preclude a widespread utilization of SDK in the ED’s across the country. An absence of practice standardization of dosing regimens, length of treatment, and management of side effects results in wide variation in practice. The designation of ketamine as a dissociative anesthetic irrespective of dosing regimen significantly limits its universal use as an analgesic with respect to perceived level of care, scope of providers’ practice and level of monitoring. Lack of formal FDA approval of SDK as a designated analgesic adversely affects the ability of health care practitioners to effectively administer this medication in the ED and on the hospital wards.\[21\]

In light of such limitations, our retrospective study, despite its limited data on safety and analgesic efficacy of SDK, provides further support for the role of ketamine in managing a variety of acute and chronic painful conditions across different age groups by describing in detail dosing regimens, routes and multitude of clinical indications. Furthermore, we believe that departmental and interdisciplinary protocols with clearly specified patient eligibility criteria as well as indications and contraindications to ketamine administration via IVP, SI, or CI should be in place before widespread use of this analgesic modality ought to be implemented in the ED.

**Limitations**

The retrospective design of the study, relatively small sample size, unreliable pain scores, and lack of documented adverse effects for 87% of patients were the major limitations of this study. In addition, data regarding prescribing information when extracted from medical records may not always be accurate. Lack of control group severely limited our ability to conclude that the results of this retrospective project were solely attributable to the SDK and not to other factors and analgesics operating and used during the same time period. Since the primary outcome of the study was the dosing regimens for IVP, SI and CI routes, dosages of individual analgesics administered before and after SDK were not abstracted.

As a result, we could not fully evaluate and compare the analgesic efficacy of SDK given by IVP, SI or CI routes as well as difference in pain score between different pain syndromes. Similarly, due to absence of documented adverse effects for all but 13% of patients, we could not make any conclusions regarding the safety of SDK that is given via IVP, SI or CI routes. Finally, the documented adverse effects among 46 patients were skewed towards the SI group due to the largest number of patients being in this group.

**CONCLUSION**

In conclusion, SDK analgesia in the ED is a viable analgesic modality for managing a variety of acute and chronic painful conditions across a wide age spectrum of patients resulting in opioid sparing and decreased need for rescue analgesia. There is a need for more robust, prospective, randomized trials that will further evaluate the analgesic efficacy and safety of short- and continuous ketamine infusion in the ED across a wide range of pain syndromes and different age groups.

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Ethical approval:** This study was approved by the hospital’s institutional review board.

**Conflicts of interest:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors have no independent disclosures or conflicts of interest.

**Contributors:** Study concept and design: SM; Acquisition, analysis, or interpretation of data: All authors; Statistical analysis: AL; Drafting of the manuscript: SM, JD; Critical revision of the manuscript for important intellectual content: SM; Study supervision: SM, JM.

**REFERENCE**

7. Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine...

Received March 10, 2018
Accepted after revision June 20, 2018